Recommended

New webinar: The path to optimisation in pharmaceutical microbiology
New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!
New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!
Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps

List view / Grid view

Issue 6 2006

 

article

Challenges in High-Content siRNA Screening

28 November 2006 | By Dr. Eberhard Krausz, HT-Technology Development Studio (TDS), Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG)

Huge progress has been made, both in RNA interference technology applied to mammalian cells and in automated microscopy to analyse gene functions upon silencing in the cellular context. Large-scale siRNA screens have been published recently, mainly applying assays that gain multi-parametric information on biological processes. It is a long way…

article

HUPO drives the creation of protein test standards

28 November 2006 | By John R. Yates, III, Department of Cell Biology, The Scripps Research Institute, Thierry Rabilloud, DBMS/BMCC, Alexander W. Bell, Montreal Proteomics Centre, McGill University and John J. M. Bergeron, Department of Anatomy and Cell Biology, McGill University, Quebec

Over the last ten years the Proteomics field has been a technologically dynamic area. New methods and techniques help drive the field to achieve more sophisticated measurements that yield increasingly larger volumes of data and information. This creates several problems.

article

Industry Insight: The measure of success

28 November 2006 | By EPR

“Getting to results faster and with higher data quality are challenges for major techniques, especially separation techniques such as LC and LC/MS.” explains Jaquemar. “Equally, solutions for secure information management are rapidly gaining in importance.”

article

Designing a program for early CNS development

28 November 2006 | By Irina Antonijevic, Douglas Craig and Christophe Gerald, Lundbeck Research USA, Inc.

Only a few innovations have been made in recent decades with regard to psychiatric, and particularly antidepressant, drugs (Insel et al., 2006) (Figure 1). This conundrum reflects, at least partly, the lack of understanding of the disease biology. This poses a challenge not only to inventive drug development, but also…

article

Pursuing hot targets in drug discovery

28 November 2006 | By Colleen B. Jonsson, Program Leader, Emerging Infectious Diseases Research, Southern Research Institute

Over the past few decades we have experienced a dramatic increase in the rate of emergence and re-emergence of infectious diseases1,2. Many of these diseases, such as SARS, resulted in fewer than 1,000 deaths, but caused an estimated 2 per cent decline gross domestic product in East Asia. The economic…

article

A roadmap for development

28 November 2006 | By EPR

Laboratory automation in pharmaceutical research is an established technology, but what does the future hold for its role in R&D? European Pharmaceutical Review asked four industry experts for their views, and you can read what they had to say in this virtual round table discussion.

article

Is the dream becoming reality?

28 November 2006 | By Andy Chang and Jean-Philippe Stephan Ph.D., Assay and Automation Technology department, Genentech, Inc

During the last decade, technical developments have dramatically changed the way cell-based assays could be implemented and used in research and development organisations. Although cell-based assays have moved into a modern era, cells are still grown and maintained in the same way as decades ago; i.e. manually. However, automation systems…

article

Polyphasic approach to microbial identification

28 November 2006 | By Hans-Joachim Anders, Marion Keller, Manfred Berchtold and Werner Hecker, Novartis Pharma Stein AG, Biological and Microbiological Services, Switzerland

The identification of microorganisms from the pharmaceutical production environment has gained an ever greater importance in modern times. Thus the new Aseptic Processing Guide of the FDA recommends the identification of detected isolates from the critical clean room area (grade A or ISO 5) down to the species level and…

article

Committee E55 – an update

28 November 2006 | By Pat Picariello, Director of Developmental Operations, ASTM International

Since its creation in December 2003, ASTM International Committee E55 on Manufacture of Pharmaceutical Products has grown in size as well as global relevance. Recent liaison relationships have been established with the ISPE and the European Compliance Academy (ECA) regarding their internal distribution of E55 draft standards for the purpose…